We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Nmn5.5
NMN Research
Likely helps
49 peer-reviewed studies
What the evidence says
Likely helps
NMN appears to help in 5 of 6 studies with measurable effects — the evidence leans clearly favourable.
Most evidence is from high-quality meta-analyses and randomised trials published 1993–2026 with a typical study size of 48 participants.
Based on 49 studies · 8 meta-analyses · 31 RCTs · 3,429 total participants
Confidence
High confidence
What the studies found
5helped1unclear· 43 more without graded effect data
39 studies in the last 5 years · Latest meta-analysis: 2026
199320092026
1Gait speedMeta-Analysisn=412 · medium study2025
NMN has positive efficacy in enhancing muscle function, reducing insulin resistance and lowering aminotransferase levels in middle-aged and elderly individuals.
Wang JP et al. · Current pharmaceutical biotechnology (2025)
Noticeable benefit
← WorseNo effectBetter →
Likely real
Based on changes in gait speed (SMD: 0.34 m/s, 95%CI [0.03, 0.66] p = 0.033), NMN had significant effects on muscle mass.
Moreover, NMN had a better effect on ALT (SMD: -0.29 IU/L, 95%CI [-0.55, -0.03] p = 0.028).
NMN has positive efficacy in enhancing muscle function, reducing insulin resistance and lowering aminotransferase levels in middle-aged and elderly individuals.
Based on the small number of RCTs involving mainly relatively healthy adults, short-term supplementation of NMN of 250-2000 mg/d did not show significantly positive impacts on glucose control and lipid profile.
3NAD+ therapy benefit/risk analysisSystematic ReviewCited 69×n=1,545 · large study2020
Potential risks in raising NAD+ levels in various clinical disorders using NAD+ precursors include the accumulation of putative toxic metabolites, tumorigenesis and promotion of cellular senescence.
Braidy N et al. · Experimental gerontology (2020)
Potential risks in raising NAD+ levels in various clinical disorders using NAD+ precursors include the accumulation of putative toxic metabolites, tumorigenesis and promotion of cellular senescence.
Therefore, NAD+ metabolism represents a promising target and further studies are needed to recapitulate the preclinical benefits in human clinical trials.Crown
Results of preclinical and clinical studies confirm the potential benefits of NAD+ precursors for the treatment of AD.
Alghamdi M et al. · Journal of Alzheimer's disease : JAD (2024)
Results of preclinical and clinical studies confirm the potential benefits of NAD+ precursors for the treatment of AD.
However, further clinical studies are required to confirm the increasingly important value of NAD+ precursors as effective pharmacological interventions in the clinic.
10Blood pressureMeta-Analysisn=349 · medium study2026
However, the potential of NMN as a viable candidate for early-stage blood pressure management requires confirmation through long-term, large-scale, high-quality RCTs in future clinical studies.
Zhang M et al. · Nutrients (2026)
Noticeable benefit
← WorseNo effectBetter →
Compared with the placebo, NMN supplementation was associated with a statistically significant but modest reduction in resting DBP (WMD, -2.15 mmHg; 95% CI: -3.68 to -0.61).
In contrast, the reduction in resting SBP was not statistically significant.
Notably, subgroup analyses revealed that NMN supplementation resulted in a significant reduction in SBP specifically among participants aged 60 years and older (WMD: -3.94 mmHg; 95% CI: -7.06 to -0.82).
In this review, we systematically summarize the impact of NMN as a nutraceutical and potential therapeutic drug on cardiovascular diseases and emphasize the correlation between NMN supplementation and cardiovascular protection.
Deng H, Ding D, Ma Y, Zhang H, Wang N, Zhang C, Yang G. · International journal of molecular sciences (2024)
Both in vivo and in vitro studies have demonstrated that nicotinamide mononucleotide (NMN), as a NAD + precursor, alleviates the development of cardiovascular diseases such as heart failure, atherosclerosis, and myocardial ischemia/reperfusion injury.
Importantly, NMN has suggested pharmacological activities mostly through its involvement in NAD + biosynthesis.
Several clinical studies have been conducted to investigate the efficacy and safety of NMN supplementation, indicating its potential role in cardiovascular protection without significant adverse effects.
This mechanistic RCT provides direct evidence that NMN enhances skeletal muscle NAD+ and improves insulin sensitivity, strengthening the translational case for NMN as a metabolic health intervention.
NMN supplementation increases blood NAD concentrations and is safe and well tolerated with oral dosing up to 900 mg NMN daily. Clinical efficacy expressed by blood NAD concentration and physical performance reaches highest at a dose of 600 mg daily oral intake.
Yi L et al. · GeroScience (2023)
Statistical analysis was performed using the Per Protocol analysis with significant level set at p = 0.05.
Blood NAD concentrations were statistically significantly increased among all NMN-treated groups at day 30 and day 60 when compared to both placebo and baseline (all p ≤ 0.001).
Walking distance increase during the six-minute walking test was statistically significantly higher in the 300 mg, 600 mg, and 900 mg groups compared to placebo at both days 30 and 60 (all p < 0.01), with longest walking distances measured in the 600 mg and 900 mg groups.
145-chair stand test performanceRCTCited 53×n=108 · medium study2022
These findings suggest the potential of NMN in preventing loss of physical performance and improving fatigue in older adults.
Kim M et al. · Nutrients (2022)
Noticeable benefit
← WorseNo effectBetter →
Significant interactions were observed between 5-STS and drowsiness. 5-STS of all groups on post-intervention and drowsiness of the NMN_PM and Placebo_PM groups on mid- and post-intervention showed significant improvement compared with those in pre-intervention.
The NMN_PM group demonstrated the largest effect size for 5-STS (d = 0.72) and drowsiness (d = 0.64).
Overall, NMN intake in the afternoon effectively improved lower limb function and reduced drowsiness in older adults.